Ovarian Cancer Clinical Trial

Enzastaurin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Summary

RATIONALE: Enzastaurin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

PURPOSE: This phase II trial is studying how well enzastaurin works in treating patients with persistent or recurrent ovarian epithelial cancer or primary peritoneal cancer.

View Full Description

Full Description

OBJECTIVES:

Primary

Assess the efficacy of enzastaurin hydrochloride, in terms of 6-month progression-free survival or objective tumor response, in patients with recurrent or persistent ovarian epithelial or primary peritoneal cancer.
Determine the nature and degree of toxicity of this regimen in these patients.

Secondary

Determine the duration of progression-free and overall survival of patients treated with this regimen.
Determine the effects of prognostic variables, including platinum sensitivity, initial performance status, and age, in patients treated with this regimen.

OUTLINE: This is a multicenter study.

Patients receive oral enzastaurin hydrochloride 3 times on day 1 and then once daily on days 2-28 of course 1. For all subsequent courses, patients receive enzastaurin hydrochloride once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed every 3 months for 2 years and then every 6 months for 3 years.

PROJECTED ACCRUAL: A total of 68 patients will be accrued for this study.

View Eligibility Criteria

Eligibility Criteria

DISEASE CHARACTERISTICS:

Histologically confirmed ovarian epithelial or primary peritoneal carcinoma
Recurrent or persistent disease

Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques OR ≥ 10 mm by spiral CT scan

Must have ≥ 1 target lesion to assess response

Tumors within a previously irradiated field are designated as "nontarget" lesions unless progression is documented or a biopsy is obtained to confirm persistence ≥ 90 days after completion of radiotherapy

Must have received 1 prior platinum-based chemotherapy regimen containing carboplatin, cisplatin, or another organoplatinum compound for management of primary disease

Initial treatment may have included high-dose therapy, consolidation therapy, or extended therapy administered after surgical or nonsurgical assessment

Must meet any 1 of the following criteria for platinum-based therapy:

Disease progression during therapy
Treatment-free interval after completion of treatment < 12 months
Disease persistence after completion of therapy
Ineligible for a higher priority GOG clinical trial

PATIENT CHARACTERISTICS:

GOG performance status 0-1 (for patients who received 2 prior treatment regimens) OR 0-2 (for patients who received 1 prior treatment regimen)
Absolute neutrophil count ≥ 1,500/mm³
Platelet count ≥ 100,000/mm³
Hemoglobin ≥ 9 g/dL (transfusions allowed)
Creatinine < 1.5 times upper limit of normal (ULN)
Bilirubin ≤ 2 times ULN
Alkaline phosphatase ≤ 3 times ULN (5 times ULN if liver metastases are present)
AST and ALT ≤ 3 times ULN (5 times ULN if liver metastases are present)
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception during and for 3 months after completion of study treatment
Able to swallow tablets
No sensory or motor neuropathy > grade 1
No active infection requiring antibiotics
No other invasive malignancies or evidence of cancer within the past 5 years except nonmelanoma skin cancer
No serious systemic disorders that would preclude study compliance, including an abnormal ECG indicative of cardiac disease

PRIOR CONCURRENT THERAPY:

See Disease Characteristics
Recovered from prior surgery, radiotherapy, or chemotherapy
At least 1 week since prior anticancer hormonal therapy
No more than 1 additional cytotoxic regimen for management of recurrent or persistent disease
At least 4 weeks since other prior anticancer therapy, including immunotherapy
At least 30 days since prior investigational drugs
No prior enzastaurin hydrochloride
No prior radiotherapy to > 25% of marrow-bearing areas
No prior noncytotoxic therapy, including bevacizumab, for recurrent or persistent disease
No prior treatment that would preclude treatment on this protocol
No concurrent chemotherapy, immunotherapy, or other experimental medications
No concurrent enzyme-inducing antiepileptic drugs, including carbamazepine, phenobarbital, or phenytoin
No other concurrent systemic anticancer therapy
No concurrent radiotherapy, including palliative radiotherapy
No concurrent agents that stimulate thrombopoiesis
No concurrent amifostine or other protective reagents
Concurrent hormone replacement therapy allowed
Concurrent bisphosphonates allowed provided bony metastases are present

Study is for people with:

Ovarian Cancer

Phase:

Phase 2

Estimated Enrollment:

28

Study ID:

NCT00407758

Recruitment Status:

Completed

Sponsor:

Gynecologic Oncology Group

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 16 Locations for this study

See Locations Near You

Jonsson Comprehensive Cancer Center at UCLA
Los Angeles California, 90095, United States
Rush University Medical Center
Chicago Illinois, 60612, United States
Decatur Memorial Hospital Cancer Care Institute
Decatur Illinois, 62526, United States
Evanston Northwestern Healthcare - Evanston Hospital
Evanston Illinois, 60201, United States
Hinsdale Hematology Oncology Associates
Hinsdale Illinois, 60521, United States
CCOP - Carle Cancer Center
Urbana Illinois, 61801, United States
St. Vincent Indianapolis Hospital
Indianapolis Indiana, 46260, United States
CCOP - Grand Rapids
Grand Rapids Michigan, 49503, United States
Hulston Cancer Center at Cox Medical Center South
Springfield Missouri, 65807, United States
Methodist Estabrook Cancer Center
Omaha Nebraska, 68114, United States
Blumenthal Cancer Center at Carolinas Medical Center
Charlotte North Carolina, 28232, United States
Oklahoma University Cancer Institute
Oklahoma City Oklahoma, 73104, United States
Rosenfeld Cancer Center at Abington Memorial Hospital
Abington Pennsylvania, 19001, United States
Fox Chase Cancer Center - Philadelphia
Philadelphia Pennsylvania, 19111, United States
McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center
Reading Pennsylvania, 19612, United States
University Cancer Center at University of Washington Medical Center
Seattle Washington, 98195, United States

How clear is this clinincal trial information?

Study is for people with:

Ovarian Cancer

Phase:

Phase 2

Estimated Enrollment:

28

Study ID:

NCT00407758

Recruitment Status:

Completed

Sponsor:


Gynecologic Oncology Group

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider